Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperinsulinemia in NAFLD Pilot Study
NCT06126354Phase 1Withdrawn
- Sponsor
- Columbia University
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Columbia University. Primary endpoints: Absolute values of plasma glucose up to 425 minutes, Relative change in plasma glucose up to 425 minutes and 4 more. Planned start Jul 2024; status: withdrawn.
Beyond the preview
Go deeper on NCT06126354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126354.